LONDON (dpa-AFX) – AstraZeneca PLC (AZN) on Monday said its pivotal Phase III MIRANDA trial of tozorakimab in patients with Chronic Obstructive Pulmonary Disease met its primary endpoint, demonstr…
AstraZeneca Says Tozorakimab Meets Main Goal In Phase III COPD Trial
Source: Finanznachrichten.de
Read Full Story →
